See more : Peel Mining Limited (PEX.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Cartesian Therapeutics, Inc. (RNAC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cartesian Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Clemondo Group AB (publ) (CLEM.ST) Income Statement Analysis – Financial Results
- Som Datt Finance Corporation Limited (SODFC.BO) Income Statement Analysis – Financial Results
- Emclaire Financial Corp (EMCF) Income Statement Analysis – Financial Results
- Allied Gaming & Entertainment Inc. (AGAE) Income Statement Analysis – Financial Results
- Cordlife Group Limited (CLIFF) Income Statement Analysis – Financial Results
Cartesian Therapeutics, Inc. (RNAC)
About Cartesian Therapeutics, Inc.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.00M | 110.78M | 85.08M | 16.60M | 6.68M | 903.00K | 207.00K | 8.08M | 6.01M | 3.04M |
| Cost of Revenue | 1.55M | 2.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 24.45M | 108.74M | 85.08M | 16.60M | 6.68M | 903.00K | 207.00K | 8.08M | 6.01M | 3.04M |
| Gross Profit Ratio | 94.03% | 98.16% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 71.84M | 72.38M | 68.74M | 54.51M | 42.74M | 47.69M | 45.17M | 29.70M | 22.98M | 10.49M |
| General & Administrative | 40.58M | 23.86M | 20.94M | 18.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.95M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 40.58M | 23.86M | 20.94M | 18.91M | 14.36M | 17.26M | 18.08M | 12.25M | 7.29M | 7.95M |
| Other Expenses | 0.00 | 330.00K | 15.00K | 89.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 110.87M | 96.24M | 89.67M | 73.42M | 57.11M | 64.95M | 63.24M | 41.95M | 30.27M | 18.44M |
| Cost & Expenses | 112.42M | 96.24M | 89.67M | 73.42M | 59.13M | 65.93M | 63.99M | 42.75M | 31.32M | 18.44M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 834.00K | 1.05M | 617.00K | 234.00K | 171.00K | 111.00K |
| Interest Expense | 2.83M | 3.03M | 2.84M | 1.56M | 1.52M | 1.49M | 1.21M | 1.25M | 948.00K | 552.00K |
| Depreciation & Amortization | 843.00K | 2.04M | 1.72M | 1.73M | 2.03M | 975.00K | 750.00K | 802.00K | 1.04M | 864.00K |
| EBITDA | -235.06M | 39.84M | -5.16M | -65.59M | -51.80M | -62.87M | -63.37M | -34.16M | -23.18M | -11.46M |
| EBITDA Ratio | -903.95% | 14.58% | -3.91% | -337.40% | -755.25% | -7,092.69% | -30,451.21% | -419.00% | -403.59% | -377.11% |
| Operating Income | -86.42M | 14.54M | -4.60M | -56.82M | -52.46M | -65.02M | -63.78M | -34.67M | -25.30M | -15.40M |
| Operating Income Ratio | -332.32% | 13.12% | -5.40% | -342.36% | -785.61% | -7,200.66% | -30,813.53% | -428.92% | -420.96% | -506.55% |
| Total Other Income/Expenses | -152.29M | 20.23M | -5.12M | -12.06M | -2.90M | -314.00K | -1.54M | -1.54M | 130.00K | 2.52M |
| Income Before Tax | -238.71M | 34.77M | -9.72M | -68.88M | -55.35M | -65.34M | -65.32M | -36.21M | -25.17M | -12.88M |
| Income Before Tax Ratio | -917.97% | 31.39% | -11.43% | -414.99% | -828.97% | -7,235.44% | -31,556.04% | -447.98% | -418.80% | -423.68% |
| Income Tax Expense | -19.00M | -609.00K | 15.97M | 1.65M | 1.86M | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -219.71M | 35.38M | -25.69M | -68.88M | -55.35M | -65.34M | -65.32M | -36.21M | -25.17M | -12.88M |
| Net Income Ratio | -844.91% | 31.94% | -30.19% | -414.99% | -828.97% | -7,235.44% | -31,556.04% | -447.98% | -418.80% | -423.68% |
| EPS | -42.49 | 7.33 | -6.74 | -20.42 | -36.46 | -87.55 | -95.94 | -103.52 | -40.50 | -38.17 |
| EPS Diluted | -42.49 | 2.98 | -6.74 | -20.42 | -36.46 | -87.55 | -95.94 | -103.52 | -40.50 | -38.17 |
| Weighted Avg Shares Out | 5.17M | 4.83M | 3.81M | 3.37M | 1.52M | 746.31K | 680.83K | 349.80K | 621.65K | 428.95K |
| Weighted Avg Shares Out (Dil) | 5.17M | 4.86M | 3.81M | 3.37M | 1.52M | 746.31K | 680.83K | 349.80K | 621.65K | 428.95K |
Cartesian Therapeutics Announces New Employment Inducement Grant
Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland
Cartesian Therapeutics Announces New Employment Inducement Grants
Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today?
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cartesian Therapeutics, Inc. (NASDAQ: RNAC) and Encourages Investors to Contact the Firm
Source: https://incomestatements.info
Category: Stock Reports